Hyderabad: Delegates of two countries Iran and India came on a single platform on Monday to build a bridge between India and Iran.This programme is especially aimed at enhancing women empowerment.
Let’s digest the bad news first. It’s likely that you’ve missed out on the Saturday buffet at Forest Produce Market in Pacific Grove. Owner Sal Rona explains that the weekly
Efforts on to revive pharma exports to Iran - The Hindu BusinessLine thehindubusinessline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindubusinessline.com Daily Mail and Mail on Sunday newspapers.
Objective To report the efficacy, safety, and exploratory immunogenicity findings of two 5 µg doses of the BIV1-CovIran vaccine.
Design Randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.
Setting In six cities of Iran, including Bushehr, Isfahan, Karaj, Mashhad, Shiraz, and Tehran. The first vaccine or placebo injection of the first participant was on 16 May 2021 in Tehran. The last vaccine or placebo injection of the last participant occurred on 15 July 2021 in Isfahan.
Participants 20 000 participants aged 18-75 years were randomly assigned to the intervention or placebo groups with a ratio of 2:1.
Intervention 5 µg vaccine or placebo with the interval of 28 days.
Main outcome measures Vaccine efficacy for a 90 day follow-up period, safety and explanatory immunogenicity assessment, and variant detection during the trial.
Results 20 000 participants were recruited and randomly assigned to receive BIV1-CovIran (n=13 335 (66.7%)) or placebo (